Roumell Again Reduces Position in Transcept Pharmaceuticals

Jim Roumell‘s hedge fund, Roumell Asset Management, in a new form 4 filed with the SEC, reported selling some shares of Transcept Pharmaceuticals Inc (NASDAQ:TSPT). In one transaction, Roumell sold 2,380 shares of Transcept at the price of $3.75 apiece. At the same time, the fund reduced its exposure in the company by another 10,410 shares that have been transferred to an investment adviser. On the whole, Roumell now holds an aggregate amount of some 2.27 million shares.

James Roumell

Last week, Roumell disclosed selling another 7,020 shares of Transcept.

Disclosure: none

Recommended Reading:

Christian Leone, Luxor Capital Increase Exposure in Hemisphere Media Group

RCS Capital Reveals 8.3% Stake in Investors Capital Holdings

3 Billionaire Buys You Should Know About